Trials / Completed
CompletedNCT03858257
High Flow Nasal Oxygen During Sedation
High Flow Nasal Oxygen During Conscious Sedation in the Cardiac Catheterisation Laboratory: A Randomized Controlled Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 129 (actual)
- Sponsor
- University Health Network, Toronto · Academic / Other
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to test the hypothesis that using high flow nasal oxygen improves ventilation during cardiac implantable electronic device procedures performed with conscious sedation. A randomized controlled trial design will be used with participants randomized in a 1:1 ratio to oxygen supplementation through a standard facemask or high flow nasal oxygen.
Detailed description
High flow nasal oxygen (HFNO) is increasingly regarded as a promising technology for oxygen delivery in critical care and anesthetic management. Although promising, further high-quality studies examining the effects of using HFNO during procedural sedation are required to inform decision-making regarding implementation of this new technology into practice. The 2018 guidelines from the American Society of Anesthesiology stated that there is insufficient evidence regarding which methods of supplemental oxygen administration (e.g., nasal cannula, face mask, or specialized devices such as HFNO) are more effective. This trial will address this limitation in the evidence base specifically in regard to the efficacy of using HFNO during conscious sedation in the cardiac catheterisation laboratory.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | High flow nasal oxygen | The Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand) will be used. |
| DEVICE | Standard oxygenation | Supplemental oxygen through a facemask. |
Timeline
- Start date
- 2019-08-07
- Primary completion
- 2020-03-12
- Completion
- 2020-03-12
- First posted
- 2019-02-28
- Last updated
- 2020-11-12
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT03858257. Inclusion in this directory is not an endorsement.